ReviewMolecular diversity2026
The architecture of computational antiviralism: a multi-scale framework from molecular targeting to viral ecosystem engineering.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recurrent outbreak of viral pathogens and the possibility of the new pandemics demand the transition to the predictive and integrative computational frameworks instead of reactive one. This review describes computational antiviralism as an integrated approach that uses artificial intelligence (AI), virtual screening, and molecular design tools to identify antiviral targets at the molecular level. We compare deep learning-based structure models with physics-based molecular dynamics (MD) with network pharmacology to describe virus-host interactome dynamics. We also evaluate systems virology strategies that combine the transcriptomic, proteomic, and metabolomic data in order to solve infection-induced cellular reprogramming. The framework is not confined to the molecular, but includes evolutionary phylogenomics, epidemiological modelling of the zoonotic spillover, and climate-guided forecasting of cross-species transmission of viruses. We consider such key issues as assay heterogeneity, interpretability of models, and management of autonomous laboratory systems. Importantly, we explicitly acknowledge that no true end-to-end validated multi-scale antiviral pipeline currently exists; the framework is presented as a forward-looking research agenda with clearly defined open challenges. Collectively, this synthesis will bring computational antiviralism as an anticipatory field of study that can catalyze the broad-spectrum antiviral discovery, as well as providing preemptive countermeasures to emergent viral challenges through coordinated molecular, cellular and ecosystem-level interventions.
Indexed as
Identifiers
42071119What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.